SCHEMBL24529801

SCHEMBL24529801

O=C(NCc1ccc(-c2nncnn2)cc1)c1ccc(F)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGDS O60760 3/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ MLLT3 P42568 1/20 0.46
▸ MLLT1 Q03111 1/20 0.46
▸ EPHX2 P34913 5/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CHRM4 P08173 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ NR1H4 Q96RI1 2/20 0.43
▸ XDH P47989 1/20 0.42
▸ HDAC1 Q13547 2/20 0.42
▸ HDAC3 O15379 1/20 0.42
▸ HDAC4 P56524 1/20 0.42
▸ HDAC7 Q8WUI4 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ HDAC10 Q969S8 1/20 0.42
▸ HDAC11 Q96DB2 1/20 0.42
▸ HDAC8 Q9BY41 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29723791 1.00 HPGDS (0.48) HPGDSL3MBTL1MLLT3MLLT1EPHX2
SCHEMBL23015033 0.84 L3MBTL1 (0.61) L3MBTL1EPHX2SMN1; SMN2CYP3A4NR1H4
SCHEMBL22893169 0.83 HPGDS (0.46) HPGDSL3MBTL1MLLT1EPHX2NR1H4
SCHEMBL29723785 0.77 KMT2A (0.53) SMN1; SMN2CYP1A2CHRM4HDAC6
SCHEMBL24529732 0.77 KMT2A (0.53) SMN1; SMN2CYP1A2CHRM4HDAC6
SCHEMBL29723794 0.77 HPGD (0.46) HPGDSL3MBTL1EPHX2SMN1; SMN2NR1H4
SCHEMBL24529730 0.77 HPGD (0.46) HPGDSL3MBTL1EPHX2SMN1; SMN2NR1H4
SCHEMBL21490291 0.75 EPHX2 (0.64) EPHX2SMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL12103897 0.74 KMT2A (0.56) EPHX2SMN1; SMN2NR1H4HDAC1HDAC3
SCHEMBL16496066 0.74 HPGDS (0.71) HPGDSL3MBTL1SMN1; SMN2HDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240034722-A1 PRETARGETING IMAGING AGENTS ELI LILLY AND COMPANY 2024-02-01 — — US disclosed
EP-4262885-A1 PRETARGETING IMAGING AGENTS Eli Lilly and Company (US) 2023-10-25 — — EP disclosed
CN-116783177-A Pretargeting imaging agent 伊莱利利公司 2023-09-19 — — CN disclosed
WO-2022132924-A1 PRETARGETING IMAGING AGENTS ELI LILLY AND COMPANY (US) 2022-06-23 — — WO disclosed
WO-2022132924-A1 PRETARGETING IMAGING AGENTS ELI LILLY AND COMPANY (US) 2022-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034722-A1 PRETARGETING IMAGING AGENTS CD47, NECTIN4, LGALS3BP HPGDS 1475/4885L3MBTL1 2463/4885MLLT3 3298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback